Neuroendocrine Disturbances in Huntington's Disease
暂无分享,去创建一个
Anne-Catherine Bachoud-Lévi | Patrick Maison | Jean-Philippe Azulay | Alexandra Durr | Emmanuel Broussolle | Pierre Krystkowiak | A. Durr | E. Broussolle | P. Krystkowiak | A. Bachoud-Lévi | J. Azulay | C. Tranchant | P. Maison | S. Moutéreau | Stéphane Moutereau | Françoise Morin | Christine Tranchant | Nadine Saleh | Françoise Morin | N. Saleh | F. Morin
[1] N. Aziz,et al. Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington Disease: Clinical Consequences and Therapeutic Implications , 2007, Reviews in the neurosciences.
[2] O. Phillipson,et al. Plasma growth hormone concentrations in Huntington's chorea. , 1976, Clinical science and molecular medicine.
[3] E. Guney,et al. TSH influences serum leptin levels independent of thyroid hormones in hypothyroid and hyperthyroid patients. , 2005, Endocrine journal.
[4] S. Doré,et al. Rediscovering good old friend IGF-I in the new millenium: possible usefulness in Alzheimer's disease and stroke. , 2000, Pharmaceutica acta Helvetiae.
[5] E Maran,et al. Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntington's Disease , 1990, Journal of neuropathology and experimental neurology.
[6] E. J. Field,et al. UNSATURATED FATTY ACIDS AND TRANSPLANTATION , 1975, The Lancet.
[7] M. Panas,et al. Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia , 2005, Annals of neurology.
[8] G. Van den Berghe. Endocrine evaluation of patients with critical illness. , 2003, Endocrinology and metabolism clinics of North America.
[9] Fabrice P Cordelières,et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.
[10] P. Chanson,et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. , 2004, The Journal of clinical endocrinology and metabolism.
[11] R. Chalmers,et al. Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea. , 1978, Journal of neurology, neurosurgery, and psychiatry.
[12] W. Tourtellotte,et al. Growth hormone and prolactin secretion in Huntington's disease. , 1979, Life sciences.
[13] F. Leblhuber,et al. Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea , 1995, Journal of the Neurological Sciences.
[14] K. Marder,et al. Weight loss in early stage of Huntington’s disease , 2002, Neurology.
[15] M. Hayden,et al. IMPAIRED PROLACTIN RELEASE IN HUNTINGTON'S CHOREA EVIDENCE FOR DOPAMINERGIC EXCESS , 1977, The Lancet.
[16] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[17] J. Willey,et al. PRESTROKE PHYSICAL ACTIVITY IS ASSOCIATED WITH SEVERITY AND LONG-TERM OUTCOME FROM FIRST-EVER STROKE , 2009, Neurology.
[18] H. Lehrach,et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. , 2004, Molecular cell.
[19] I. Bone,et al. Studies of hypothalamic function in Huntington's chorea. , 1981, Journal of neurology, neurosurgery, and psychiatry.
[20] F. Sundler,et al. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease , 2005, The European journal of neuroscience.
[21] M. Ranke,et al. Magnetic resonance images of 91 children with different causes of short stature: pituitary size reflects growth hormone secretion , 1997, European Journal of Pediatrics.
[22] D. Cocchi,et al. Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea. , 1977, The Journal of clinical endocrinology and metabolism.
[23] S. Podolsky,et al. Growth hormone abnormalities in Huntington's chorea: effect of L-dopa administration. , 1974, The Journal of clinical endocrinology and metabolism.
[24] L. Murri,et al. Circadian rhythmicity of prolactin secretion in Huntington's chorea. , 1980, Life sciences.
[25] G. Bruyn,et al. Pathogenesis of Huntington's chorea. , 1973, Lancet.
[26] S. Podolsky,et al. Exaggerated growth hormone response to arginine infusion in Huntington's disease. , 1975, The Journal of clinical endocrinology and metabolism.
[27] P. Mantegazza,et al. PROLACTIN CONTROL IN HUNTINGTON'S CHOREA , 1977, The Lancet.
[28] J. Loeffler,et al. Neuroendocrinology of Neurodegenerative Diseases , 2003, Neuroendocrinology.
[29] R. Sapolsky,et al. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. , 2000, Archives of general psychiatry.
[30] Gordon J. Gilbert. WEIGHT LOSS IN HUNTINGTON DISEASE INCREASES WITH HIGHER CAG REPEAT NUMBER , 2009 .
[31] E. Caine,et al. Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release. , 1978, Life sciences.
[32] H. Kremer,et al. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease , 1991, Neuroscience Letters.
[33] H. Herken,et al. Increased Levels of Nitric Oxide, Cortisol and Adrenomedullin in Patients with Chronic Schizophrenia , 2007, Medical Principles and Practice.
[34] S. Folstein,et al. Sexual disorders in Huntington's disease. , 1994, The Journal of neuropsychiatry and clinical neurosciences.
[35] F. Casanueva,et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. , 2004, European journal of endocrinology.
[36] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[37] I. Torres-Aleman,et al. Neurodegeneration Is Associated to Changes in Serum Insulin-like Growth Factors , 2000, Neurobiology of Disease.
[38] H. Tanila,et al. Orexin loss in Huntington's disease. , 2005, Human molecular genetics.
[39] I. Heuser,et al. The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease , 1991, Biological Psychiatry.
[40] Jane S. Paulsen,et al. Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.
[41] H. Fibiger,et al. BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS , 1981, The Medical journal of Australia.
[42] I. Shoulson,et al. Huntington disease , 1981, Neurology.
[43] J Kassubek,et al. Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[44] S. W. Davies,et al. Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.